The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study

Diabetes and Vascular Disease Research

Volumn 14, Issue 4, 2017, Pages 295-303

  Jil, Mamza ^a   Rajnikant, Mehta ^a   Richard, Donnelly ^a   Iskandar, Idris ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

cardiovascular; gliptins; Insulin; intensification

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RETROSPECTIVE STUDY; THERAPY EFFECT; AGED; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHI SQUARE DISTRIBUTION; COMPLICATION; HEART INFARCTION; KAPLAN MEIER METHOD; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85020935644     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164116687102     Document Type: Article

References (31)

1. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
2. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
4. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents. 2009, http://www.nice.org.uk/guidance/CG87
5. National Institute for Health and Clinical Excellence. Type 2 diabetes in adults: management (No. 28). London: National Institute for Health and Clinical Excellence, 2015.
6. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
7. Gamble JM, Simpson SH, Eurich DT, et al. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 2010; 12: 47-53.
8. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
9. Currie CJ, Poole CD, Evans M, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013; 98: 668-677.
10. Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014; 311: 2288-2296.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
12. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
13. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
14. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
15. Muniyappa R, Montagnani M, Koh KK, et al. Cardiovascular actions of insulin. Endocr Rev 2007; 28: 463-491.
16. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013; 166: 983.e7-989.e7.
17. Idris I, Warren G, Donnelly R., Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med 2012; 172: 1005-1011.
18. Austin PC., The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242-1258.
19. Haviland A, Nagin DS, Rosenbaum PR., Combining propensity score matching and group-based trajectory analysis in an observational study. Psychol Methods 2007; 12: 247-267.
20. Grambsch PM, Therneau TM., Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526.
21. Van Buuren S, Boshuizen HC, Knook DL,. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681-694.
22. StataCorp. Stata statistical software: release 13. College Station, TX: StataCorp LP, 2013.
23. Ray WA., Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
24. Rosenbaum PR, Rubin DB., Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. J Roy Stat Soc B Met 1983; 45: 212-218.
25. Klein JP, Moeschberger ML., Survival analysis techniques for censored and truncated data. New York: Springer, 1997.
26. Busso M, DiNardo J, McCrary J., New evidence on the finite sample properties of propensity score reweighting and matching estimators. Rev Econ Stat 2014; 96: 885-897.
27. Rensing KL, Reuwer AQ, Arsenault BJ, et al. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? Diabetes Obes Metab 2011; 13: 1073-1087.
28. Van Avendonk MJ, Rutten GE,. Insulin therapy in type 2 diabetes: what is the evidence? Diabetes Obes Metab 2009; 11: 415-432.
29. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749-758.
30. Cho E, Manson JE, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease among diabetic women. Diabetes Care 2002; 25: 1142-1148.
31. Owen V, Seetho I, Idris I., Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes. Diabetes Obes Metab 2010; 12: 865-870.